Skip to main content

Table 2 Dose-dependent reduction of clinical parameters by liposomal dexamethasone phosphate on Days 19 and 28 in adjuvant arthritis

From: Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis

Experiment 4   Arthritis score Paw volume
Treatment   Day 19 Day 28 Day 19 Day 28
AA/PBS   -- -- -- --
AA/DxM-P 0.01 mg/kg -10% ± 9.3% + 6% ± 11.9% -18% ± 12.9% -12% ± 8.4%
AA/DxM-P 0.1 mg/kg -25% ± 6.9% -4% ± 10.3% -34% ± 10.1% + 9% ± 27.0%
AA/DxM-P 1.0 mg/kg -69% ± 12.5% + -27% ± 16.4% -71% ± 10.4% + -23% ± 16.0%
AA/liposomal DxM-P 0.01 mg/kg -20% ± 14.0% -13% ± 18.5% -21% ± 21.1% -5% ± 26.7%
AA/liposomal DxM-P 0.1 mg/kg -38% ± 23.7% -28% ± 16.9% -44% ± 15.4% -36% ± 12.2%
AA/liposomal DxM-P 1.0 mg/kg -96% ± 2.0% ++ $$ § * -59% ± 20.0% -86% ± 5.1% ++ $$ §§ -58% ± 18.0%
  1. Reduction of arthritis score and paw volume on Day 19 (maximal efficacy of therapy) and Day 28 of AA after treatment with free DxM-P (3 × 1 mg/kg, 3 × 0.1 mg/kg, or 3 × 0.01 mg/kg) or liposomal DxM-P (3 × 1 mg/kg, 3 × 0.1 mg/kg, or 3 × 0.01 mg/kg) compared to AA/PBS (Experiment 4 corresponds to the data in Figure 2).
  2. Data are expressed as means ± standard error of the mean.
  3. + P ≤ 0.05, ++ P ≤ 0.01 vs. AA/PBS; $$ P ≤ 0.01 vs. AA/liposomal DxM-P 0.01 mg/kg; § P ≤ 0.05, §§ P ≤ 0.01 vs. AA/liposomal DxM-P 0.1 mg/kg; * P ≤ 0.05 vs. AA/DxM-P 1 mg/kg.